WO2022006117A1 - Traitement de la mucosite par photobiomodulation - Google Patents

Traitement de la mucosite par photobiomodulation Download PDF

Info

Publication number
WO2022006117A1
WO2022006117A1 PCT/US2021/039629 US2021039629W WO2022006117A1 WO 2022006117 A1 WO2022006117 A1 WO 2022006117A1 US 2021039629 W US2021039629 W US 2021039629W WO 2022006117 A1 WO2022006117 A1 WO 2022006117A1
Authority
WO
WIPO (PCT)
Prior art keywords
spot
laser
laser beam
oral cavity
target area
Prior art date
Application number
PCT/US2021/039629
Other languages
English (en)
Inventor
Bradley Sean SCHOENGOOD
Original Assignee
Schoengood Bradley Sean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schoengood Bradley Sean filed Critical Schoengood Bradley Sean
Publication of WO2022006117A1 publication Critical patent/WO2022006117A1/fr
Priority to US17/985,731 priority Critical patent/US11925816B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0606—Mouth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0627—Dose monitoring systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0644—Handheld applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Definitions

  • the invention relates generally to the treatment of mucositis, and, more specifically, to the treatment of mucositis using a focused laser beam.
  • Mucositis is a complication of cytotoxic cancer treatments, such as chemotherapy and radiation.
  • cytotoxic cancer treatments such as chemotherapy and radiation.
  • the rapidly dividing epithelial cells of the gastro-intestinal cells can break down. This leaves the mucosal lining susceptible to many classes of damage, for instance ulceration and infection.
  • the mucosa virtually lines every organ in the body from the gastrointestinal tract to the pulmonary tree. This point is important given that we are presenting a novel treatment that has the potential to treat the any mucosal lining affected by cancer treatment.
  • the oral cavity including the cheeks, lips, gums, inner cavity, and tonsillar region — all of the soft tissues is the most common location for mucositis.
  • Oral Mucositis is likely the most common, debilitating complication of cancer treatments, especially chemotherapy and radiation. Symptoms and sequelae typical of oral mucositis include red, shiny, or swollen mouth and gums, blood in the mouth, sores in the mouth or on the gums or tongue, soreness or pain in the mouth or throat, difficulty swallowing or talking, and xerostomia, mild burning, or pain when eating food.
  • oral mucositis presents in an extreme form called confluent mucositis, in which case the mucous membrane of the patient’s entire mouth and tongue can be coated by a white mucus coating that is up to a millimeter thick, making it nearly impossible to eat. It has a significant effect on the patient’s quality of life and can be dose-limiting with respect to the cancer treatment, a highly undesirable consequence of mucositis when the cancer team is trying to adequately treat a malignancy.
  • Treatment options today are limited once mucositis sets in. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, there is not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient’s ability to eat and speak.
  • PBM photobiomodulation
  • LED light emitting diode
  • LLLT low laser light therapy
  • PBM functions according to first law in photochemistry [Grotthuss-Draper law]. According to this law, light must be absorbed by a chemical substance in order to generate photochemical reaction.
  • that chemical substance is represented by the respiratory enzyme Cytochrome C oxidase, which is involved in the electron transport chain that occurs in the mitochondria of cells.
  • Mitochondria are the “powerhouse” of the cell, the subcellular organelle in which the TCA cycle takes place, allowing an oxygen molecule to be converted into 46 ATP (adenosine triphosphate), the form of energy that is usable by the human body. It is believed that low-level radiation is absorbed by intracellular photoreceptors in the membrane of the mitochondria. The effects include a reduction in pain due to increased endorphins, reduction in inflammation via reduction in interleukin-1 and C-reactive protein and tissue healing effects as a result of increased neovascularization and macrophage activity.
  • Applicant recognizes that by administering PBM therapy using a relatively high-powered spot of far red to near infrared (NIR) laser light, rather than diffused light, the effectiveness of the PBM therapy is enhanced significantly. More specifically, Applicant has developed an approach/device which emits a laser light having a precisely controlled spot size. The small spot size compared to a diffused light intensifies the dose of light at the target, thereby eliminating the need to contact the tissue with the device. Indeed, often the oral cavity can be treated without inserting the device in the mouth if the laser spot can be directed at the target area from outside the mouth.
  • NIR near infrared
  • the high-energy laser spot reaches deep into the tissue to create a more powerful therapeutic anti-inflammatory, anti edema and analgesic effect speeding up the healing process at the same time.
  • the small laser spot size in combination with the far-red to NIR light e.g. 800 - 840nm
  • the far-red to NIR light is particularly effective at stimulating mitochondria. For example, in one embodiment, an 1-2 minute exposure per 10cm2 of target area was found to be sufficient to initiate mitochondrial stimulation.
  • the device is handheld and maneuverable, therefore allowing the user to control the spot size on the target area for a given duration with a high degree of control and precision. This is particularly beneficial given the relatively high energy of the laser spot and the need to control it carefully.
  • the device is able to transfer laser energy more efficiently to the anatomical structures to which the therapy is directed in comparison with traditional laser emissions.
  • the emissions By having full control of the precise spot size, the emissions, the distribution of energy into the tissues, becomes more homogenous, in contrast to older generation lasers.
  • This in part, explains the increased efficacy and longer-term outcomes seen with the approach of the present invention.
  • the result is a hand-held portable laser technology which has an optically sophisticated precise and adjustable spot-size laser beam that works on a specific area throughout the oral cavity, including the oropharynx, to (a) reduce intensity and duration of pain; (b) shorten healing and rehabilitation period; and (c) increase quality of life and peace of mind with regards patient’s recuperation.
  • the present invention relates to a method for treating an oral cavity malady of a patient, comprising: (a) applying a spot of a laser beam to a target area around the oral cavity, the laser beam having a wavelength of about 800 to 840nm and a power of between 1000 and 4000mW, and wherein the spot has a spot size of about 3 mm to about 3.5 mm; and (b) moving the spot on the target area for a treatment time sufficient to deliver a dose of about 0.5 to about 30 J/cm2 to the target area.
  • the present invention relates to a device for treating an oral cavity malady of a patient, comprising: (a) a hand-held housing; (b) at least one laser disposed in the housing and configured for emitting a laser beam have a peak wavelength of 800 - 840nm, and a power of 1000 - 4000 mW; (c) at least one battery for powering the laser; (d) a display screen for displaying at least a duration of time the laser is operating; (e) operator controls for at least starting and stopping the laser.
  • Fig. 1 shows the top view of one embodiment of the device of the present invention.
  • Fig. 2 shows a side view of the embodiment of Fig. 1.
  • the present invention relates to a method for treating an oral cavity malady of a patient, comprising: (a) applying a spot of a laser beam to a target area around the oral cavity, the laser beam having a wavelength of about 800 to 840nm and a power of between 1000 and 4000mW, and wherein the spot has a spot size of about 2 mm to about 10 mm; and (b) moving the spot on the target area for a treatment time sufficient to deliver a dose of about 0.5 to about 30 J/cm2 to the target area.
  • a device 100 of the present invention for treating mucositis using photobiomodulation it is shown.
  • the device comprises: a hand-held housing 101; at least one laser (not shown) disposed in the housing and configured for emitting a laser beam have a peak wavelength of 800 - 840nm, and a power of 1000 - 4000 mW; at least one battery (not shown) disposed in the housing for powering the laser; a display screen 102 for displaying an indication of at least a treatment time; and operator control 103 for at least starting and stopping the laser.
  • oral cavity refers to the mouth and upper part of the throat, and includes, the lips, the lining inside the cheeks and lips, the tongue, the upper and lower gums, the floor of the mouth under the tongue, the bony roof of the mouth, area behind the wisdom teeth, and the upper part of throat; and the term “oral cavity malady” refers to any pain, wound, infection, infestation, etc.
  • the oral cavity includes, for example, mucositis, gingivitis, stomatitis, cankers, sores, ulcers, muscular tension problems resulting from procedures that cause inflammation (extractions, root canal work, dental implants, interventions on soft tissue, etc.), post-surgery pain after interventions for inserting dental implants; healing is also promoted (and as a result less analgesics need to be taken), muscle tension preventing bite registration, and trigeminal neuralgia, just to name a few.
  • One aspect of the invention is Applicant’s discovery of an effective wavelength for the laser beam for stimulating the mitochondria to treat mucositis.
  • is laser beam has a wavelength of about 800 - 840nm, or, in another embodiment, about 810 - 830 nm, or, in another embodiment, about 810 or about 830 nm.
  • the laser is a continuous beam laser.
  • the laser beam has a power of 1000 to 4000 mW, or, in another embodiment, a power of 1500 to 3000mW, or, in another embodiment, a power of about 2000 mW. In one embodiment, the power is no greater than about 2000mW to reduce the potential for pain, bleeding, ablation, and damage to tissues.
  • the dose of laser light for stimulating the mitochondria is a function of several factors including energy of beam, spot size, treatment area and treatment time.
  • the dose is about 0.5 to about 30 J/cm2, or, in one embodiment, about 5 to about 25 J/cm2, or, in one embodiment, about 10 to about 24J/cm2, or, in one embodiment, about 2 to about 10 J/cm2, or, in one embodiment, about 2 to about 4J/cm2.
  • the dose of light is determined based upon a number of variables including thickness of the tissue being treated.
  • Yet another aspect of the invention is Applicant’s control over the dose by varying spot size.
  • the dose is inversely proportional to the spot size.
  • the spot size is about 1 mm to 10mm, or, in one embodiment, about 2mm to 6mm, or, in one embodiment, about 3 mm to 4mm.
  • the spot size of the laser can be controlled by varying the distance between the device and the target area. For example, in one embodiment, varying the distance from about 2 to 5cm results in a spot size change of about 1 to about 4 mm.
  • the spot size is controlled by adjusting an optical component (e.g., lens, or focal distance) of the device emitting the laser beam.
  • the laser spot Because of the relatively high power of the laser spot, it is important to keep the laser spot moving continuously, and avoiding holding it in one location for too long. For example, suitable results have been obtained by holding the laser beam spot in the same location for no longer than 5 seconds, or for no longer than 3 seconds. Those of skill in the art will be able to determine, without undue experimentation, the proper rate at which to move the laser spot in light of this disclosure.
  • the laser spot is applied to tissue by moving the laser spot is a circular motion in the treatment area.
  • the device is configured to alert the user that the laser spot has been focused on the same location for too long.
  • the device comprises one or more accelerometers to ensure that the device is always moving when the laser beam is being emitted, and to alert the user to modify the rate at which the laser spot is being moved to ensure optimal results.
  • the device comprises a timer to ensure that the user delivers the laser energy for the appropriate treatment time.
  • this time can be entered by the user into the device.
  • the device then monitors the time that the laser is emitting, and either stops emitting the laser beam once the treatment time is reached, or alerts the user that treatment time has expired. In one embodiment, if the user stops the laser beam before treatment time is expired, the timer pauses until the user starts the laser again.
  • the treatment area may be extraoral or intraoral.
  • the laser does not necessarily go into the mouth unless the patient develops a lesion inside the mouth that needs to target. Instead, in one embodiment, treatment is performed in various sites (e.g., five) along a patient’s face and along the jaw line. In one embodiment, the procedure also involves treating a patient’s tongue. Even if the treatment is intraoral, there is typically no need to insert the device in the patient’s mouth. Rather, if there is line-of-sight between the opening of the patient’s mouth and the target area, the laser beam can be applied from outside the patient’s mouth. It is generally preferred for the patient to wear glasses configured to block or reflect a significant portion of light at about 800 to 840 nm during the procedure.
  • the mechanism by which the laser affects cells is understood to be based on bio-stimulation. It is believed that low level radiation is absorbed by intracellular photoreceptors in the membrane of the mitochondria. The effects include a reduction in pain due to increased endorphins, reduction in inflammation via reduction in interleukin-1 and C-reactive protein and tissue healing effects as a result of increased neovascularization and macrophage activity. In one embodiment, the treatment time is sufficient to increase neutrophil count to above 1000 cell/nm 3 , or, in one embodiment, above 1200 cell/nm 3 .
  • the method and device of present invention may be used to treat a variety of different oral cavity maladies including mucositis, gingivitis, stomatitis, cankers, sores, ulcers, muscular tension problems resulting from procedures that cause inflammation (extractions, root canal work, dental implants, interventions on soft tissue, etc.), post-surgery pain after interventions for inserting dental implants; healing is also promoted (and as a result less analgesics need to be taken), muscle tension preventing bite registration, and trigeminal neuralgia. Additionally, the device and method of the present invention can be used for preoperative treatments as well.
  • the device 100 of the present invention is shown. It should be understood that this embodiment is just one embodiment, and the device may take on different forms.
  • the housing 101 of the device 100 is angled. Although the angle in Fig. 2 is shown to be 39°, the device may be configured with other angles including, for example, from about 10° to about 60°, or from 20° to about 50°, or from 30° to about 40°.
  • a power supply supplies power from batteries (e.g., rechargeable batteries) located in the housing to one or more laser diodes, and a microcontroller (not shown) provides timing functionality.
  • batteries e.g., rechargeable batteries
  • a microcontroller not shown
  • a removable cap may be used to prevent accidental laser emission.
  • depressing a tail switch 104 powers on the unit when operating by battery power.
  • the display 102 illuminates.
  • Display 102 displays treatment information to the user.
  • an embedded software program controls the timing of the treatment as below above. The unit is powered down by pressing the power button.
  • the device is operated in either of two modes: (1) a timer mode where treatment time is entered, and the device automatically shuts off when the set time is reached; and (2) a manual mode where treatment continues until the device is manually shut off.
  • a timer mode where treatment time is entered, and the device automatically shuts off when the set time is reached
  • a manual mode where treatment continues until the device is manually shut off.
  • depressing a tail switch 104 powers on the unit when operating by battery power.
  • the display 102 illuminates.
  • Display 102 displays treatment information to the user.
  • an embedded software program controls the timing of the treatment as below above. The unit is powered down by pressing the power button.
  • timer button 105 which puts the device in timer mode, and then sets the time by pressing the up button 107 to toggle through time increments (e.g., 15 second, 30 second, etc.).
  • the treatment time is displayed on display 102.
  • Pressing the start/stop button 106 causes the device to power the laser.
  • the laser emits in CW mode.
  • Pressing the start/pause button again causing the device to stop/pause the laser, and, in one embodiment, the timer also stops/pauses.
  • the start button is pressed again, the timer will start from where it left off. Pressing timer button 105 resets the time to 00:00.
  • a user presses the CW button 108, which puts the device in manual or CW mode.
  • the user presses start button 106 to use the laser in continuous wave mode. Repeatedly pressing the start button 106 will cause the laser to toggle on and off.
  • the above-described process steps are described with reference to a particular ordering of process actions. However, the ordering of many of the described process actions may be changed without affecting the scope or operation of the disclosure.
  • the specification and drawings are, accordingly, to be regarded in an illustrative sense rather than in a restrictive sense.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiation-Therapy Devices (AREA)
  • Laser Surgery Devices (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

Selon l'invention, une méthode de traitement d'une maladie de la cavité buccale d'un patient comprend : l'application d'un point d'un faisceau laser à une zone cible autour de la cavité buccale, ledit faisceau laser ayant une longueur d'onde d'environ 800 à 840 nm et une puissance comprise entre 1 000 et 4 000 mW, ledit point ayant une taille de point d'environ 1 à environ 10 mm ; le déplacement dudit point sur ladite zone cible pendant une durée de traitement suffisante pour distribuer une dose d'environ 0,5 à environ 30 J/cm2 à ladite zone cible.
PCT/US2021/039629 2020-06-29 2021-06-29 Traitement de la mucosite par photobiomodulation WO2022006117A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/985,731 US11925816B2 (en) 2020-06-29 2022-11-11 Treatment of mucositis using photobiomodulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063102757P 2020-06-29 2020-06-29
US63/102,757 2020-06-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/985,731 Continuation US11925816B2 (en) 2020-06-29 2022-11-11 Treatment of mucositis using photobiomodulation

Publications (1)

Publication Number Publication Date
WO2022006117A1 true WO2022006117A1 (fr) 2022-01-06

Family

ID=79315568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/039629 WO2022006117A1 (fr) 2020-06-29 2021-06-29 Traitement de la mucosite par photobiomodulation

Country Status (2)

Country Link
US (1) US11925816B2 (fr)
WO (1) WO2022006117A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925816B2 (en) 2020-06-29 2024-03-12 Ronald L. Rubin Treatment of mucositis using photobiomodulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020120312A1 (en) * 2001-02-27 2002-08-29 Ignatius Ronald W. Device for the treatment of mucositis
US20090054953A1 (en) * 2004-08-05 2009-02-26 Photo Therapeutics Limited Phototherapeutic Method and Apparatus
US20150112411A1 (en) * 2013-10-18 2015-04-23 Varaya Photoceuticals, Llc High powered light emitting diode photobiology compositions, methods and systems
US20190254775A1 (en) * 2018-02-19 2019-08-22 Millennium Healthcare Technologies, Inc. Dental lasing device system and method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU595580B2 (en) * 1986-06-30 1990-04-05 Medical Laser Research Co., Ltd. Semiconductor laser therapeutic apparatus
CA2542246A1 (fr) * 2003-10-08 2005-04-21 Eric Bornstein Utilisation d'emission optique secondaire en tant que nouvelle technologie de ciblage de biofilm
US9265967B2 (en) * 2011-08-05 2016-02-23 Lumimed, Llc Apparatus and method for treating rhinitis
US20160279436A1 (en) * 2015-03-23 2016-09-29 Bwt Property, Inc. Phototherapy Apparatus with Dosage Control
WO2022006117A1 (fr) 2020-06-29 2022-01-06 Schoengood Bradley Sean Traitement de la mucosite par photobiomodulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020120312A1 (en) * 2001-02-27 2002-08-29 Ignatius Ronald W. Device for the treatment of mucositis
US20090054953A1 (en) * 2004-08-05 2009-02-26 Photo Therapeutics Limited Phototherapeutic Method and Apparatus
US20150112411A1 (en) * 2013-10-18 2015-04-23 Varaya Photoceuticals, Llc High powered light emitting diode photobiology compositions, methods and systems
US20190254775A1 (en) * 2018-02-19 2019-08-22 Millennium Healthcare Technologies, Inc. Dental lasing device system and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE FREITAS LUCAS FREITAS; HAMBLIN MICHAEL R: "Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy", IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS, vol. 22, no. 3, 1 May 2016 (2016-05-01), USA, pages 1 - 17, XP011613545, ISSN: 1077-260X, DOI: 10.1109/JSTQE.2016.2561201 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925816B2 (en) 2020-06-29 2024-03-12 Ronald L. Rubin Treatment of mucositis using photobiomodulation

Also Published As

Publication number Publication date
US20230074559A1 (en) 2023-03-09
US11925816B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
JP4257718B2 (ja) 電磁放射線治療法
US20080077204A1 (en) Optical biofilm therapeutic treatment
EP1888172A2 (fr) Dispositif de therapie photonique
US20150056568A1 (en) Optical therapeutic treatment device
US11925816B2 (en) Treatment of mucositis using photobiomodulation
US20090047618A1 (en) Handset and Optical Tip for Photosynthesis
WO2019088939A1 (fr) Capuchon de cicatrisation d'implant dentaire avec source de lumière à del intégrée pour thérapie photodynamique
US7160287B1 (en) Apparatus and method for performing radiation energy treatments
US20060212100A1 (en) Non-intrusive laser irradiation device
NZ543968A (en) Photo-activated disinfection
Aldelaimi et al. Using of diode laser (940 nm) in orofacial region
US20070276454A1 (en) Apparatus for Illuminating a Zone of Mammalian Skin
US6875226B2 (en) Laser therapy apparatus and laser therapy
Shetty Lasers in Orthodontics
RU203690U1 (ru) Устройство для физиотерапевтического воздействия на слизистую оболочку альвеолярного отростка верхней челюсти
WO2023227130A1 (fr) Appareil d'hygiène buccale, système et procédé d'utilisation
Pinheiro et al. LILT in the treatment of disorders of the maxillofacial region
Khan et al. Low Level Laser Therapy for Non-Invasive Dental applications: A Review
WO2024082022A1 (fr) Instruments et méthodes procédurales correspondants pour mettre en oeuvre une thérapie de photobiomodulation
El Hallal Category Archives: Uncategorised
KR20230125364A (ko) 저출력 레이저를 이용한 오랄 빔 치료기
WO2022172161A1 (fr) Traitement de l'acné
EA041432B1 (ru) Излучающее поляризованный свет медицинское устройство для профилактики и лечения гингивальных и пародонтальных заболеваний
Roukoz et al. Pain Relief of Aphthous Ulcers by Lasers: A Literature Review
WO2024089621A1 (fr) Systèmes et méthodes de traitement d'états parodontaux avec de la lumière

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21834127

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21834127

Country of ref document: EP

Kind code of ref document: A1